NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

MULTIPLE TECHNOLOGY APPRAISAL

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes [ID756]

The following documents are made available to the consultees and commentators:

1. **Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)**

2. **Consultee and commentator comments on the Appraisal Consultation Document** from:
   - AstraZeneca
   - Boehringer Ingelheim
   - Janssen
   - Healthcare Improvement Scotland
   - Merck Sharpe and Dohme
   - *Royal College of Nursing – no comments*
   - *Department of Health – no comments*

3. **Comments on the Appraisal Consultation Document from experts:**
   - Dr Peter Winocour, Consultant Physician and Clinical Director , nominated by organisation representing Janssen – clinical expert

4. **Assessment Group comments on responses to ACD**

5. **Assessment Group comments on responses to ACD - Addendum**

Any information supplied to NICE which has been marked as confidential has been redacted. All personal information has also been redacted.